The Leukemia & Lymphoma Society (LLS), transitioning to Blood Cancer United in August 2025, is a global nonprofit founded in 1949. It is dedicated to curing blood cancers and improving the quality of life for patients and their families. LLS is the largest voluntary health organization focused on blood cancer, having invested over $1.8 billion in research and serving a wide network of patients, caregivers, and healthcare professionals.
LLS's mission is to cure various blood cancers, including leukemia and lymphoma, while enhancing patient support. The organization is the largest nonprofit funder of blood cancer research, committing nearly $1.3 billion to advancements in immunotherapy and personalized medicine. LLS also provides free information, education, and support services to help patients navigate their diagnosis and treatment. Additionally, LLS advocates for improved access to care and increased research funding at both federal and state levels.
Washington, United States of AmericaNon-ProfitEnterprise
Operator of a supermarket chain company based in the Bronx, New York. The company serves fresh, seasonally appropriate food and also offers catering services for customers' personal or corporate demands and customizes the menu to meet individual needs.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lungmore